GoodRx (NASDAQ: GDRX) share price drops 2.8% on insider selloff
The share price of GoodRx Holdings, Inc. (NASDAQ: GDRX) fell 2.8% on Thursday after an insider sold shares of the company. The stock traded at $ 33.66 and last traded at $ 34.02. 29,984 shares changed hands during trade, a decrease of 98% from the average session volume of 1,547,774 shares. The stock had previously closed at $ 34.99. Specifically, an insider Andrew Slutsky sold 20,000 shares in a transaction dated Friday, October 22. The shares were sold at an average price of $ 46.74, for a total trade of $ 934,800.00. The transaction has been disclosed in a legal file with the SEC, which can be accessed via the SEC website. In addition, the main shareholder Abdiel Capital Management, Llc sold 99,135 shares in a transaction dated Wednesday, December 15. The stock was sold for an average price of $ 35.97, for a total trade of $ 3,565,885.95. Disclosure of this sale can be found here. Insiders have sold 2,019,021 shares of the company valued at $ 80,999,267 in the past ninety days. Insiders own 1.43% of the company’s shares.
A number of research companies have recently weighed in on GDRX. Zacks investment research downgraded GoodRx’s shares from a “hold” rating to a “sell” rating in a report released Thursday, November 18. Barclays raised its price target for GoodRx stock from $ 45.00 to $ 47.00 and rated the stock “overweight” in a report released on Thursday, November 11. Deutsche Bank Aktiengesellschaft lowered its target price on GoodRx shares from $ 47.00 to $ 44.00 and set a “hold” rating on the share in a report released on Monday, November 15. Morgan Stanley raised its target price on the GoodRx stock from $ 38.00 to $ 41.00 and gave the stock an “equal weight” rating in a report released on Friday, December 17. Finally, SVB Leerink lowered its target price on GoodRx shares from $ 56.00 to $ 49.00 and set an “outperformance” rating on the share in a report released on Thursday, November 11. One analyst assigned a sell rating to the stock, three assigned a conservation rating, and ten assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $ 47.57.
The stock’s 50-day moving average price is $ 40.88, and its two-hundred-day moving average price is $ 38.42. The stock has a market cap of $ 13.64 billion, a P / E ratio of -47.99, a P / E / G ratio of 35.07 and a beta of -0.69. The company has a current ratio of 14.47, a rapid ratio of 14.47 and a debt ratio of 0.78.
GoodRx (NASDAQ: GDRX) last released its results on Wednesday, November 10. The company reported earnings per share of $ 0.09 for the quarter, beating the Zacks’ consensus estimate of $ 0.01 by $ 0.08. GoodRx had a negative net margin of 41.36% and a negative return on equity of 31.61%. In the same quarter of the previous year, the company posted ($ 0.25) earnings per share. On average, equity research analysts predict that GoodRx Holdings, Inc. will post 0.03 earnings per share for the current year.
Institutional investors and hedge funds have recently increased or reduced their holdings in the stock. Creative Financial Designs Inc. ADV purchased a new position in GoodRx in the third quarter valued at approximately $ 55,000. First Horizon Advisors Inc. increased its holdings in GoodRx by 208.2% in the 3rd quarter. First Horizon Advisors Inc. now owns 1,350 shares of the company valued at $ 42,000 after purchasing an additional 912 shares during the period. Pinnacle Holdings LLC purchased a new position in GoodRx in Q3 valued at $ 91,000. AdvisorNet Financial Inc increased its holdings in GoodRx by 26.0% in the 3rd quarter. AdvisorNet Financial Inc now owns 2,425 shares of the company valued at $ 99,000 after purchasing an additional 500 shares during the period. Finally, PNC Financial Services Group Inc. increased its holdings in GoodRx by 1,828.6% in the second quarter. PNC Financial Services Group Inc. now owns 2,700 shares of the company valued at $ 97,000 after purchasing an additional 2,560 shares during the period. 51.29% of the shares are held by institutional investors.
GoodRx Company Profile (NASDAQ: GDRX)
GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that allow consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with organized and geographically relevant prescription prices, and access to negotiated prices through GoodRx codes which are used to save money on prescriptions across states. -United.
See also: What is an EV stock
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team before publication. Please send any questions or comments about this story to [email protected]
Should you invest $ 1,000 in GoodRx now?
Before you consider GoodRx, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated and top-performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts quietly whisper to their clients to buy now before the broader market takes hold … and GoodRx was not on the list.
While GoodRx currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better bets.
See the 5 actions here